Preparation method of arteplase-loaded nano-particles HMP (at) rt-PA for removing active oxygen
By preparing HMP@rt-PA with mesoporous polydopamine nanoparticles loaded with alteplase, the problem of limited treatment time window and reactive oxygen production during ischemic stroke is solved, and the problem of ischemic stroke is achieved. Rapid drug release and ROS clearance at the site improve the microenvironment of the cerebral ischemic site, improve treatment effect and reduce toxicity risk.
Patent Information
- Application Number
- CN202411284610.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-13
- Publication Date
- 2024-11-26
AI Technical Summary
Prior Art In the treatment of ischemic stroke, the time window for alteplase (rt-PA) treatment is limited and single thrombolytic therapy may cause secondary damage due to reactive oxygen species (ROS), and lack effective anti-anti- Oxidants to relieve symptoms of cerebral ischemia.
Mesoporous polydopamine nanoparticles (MPDA NPs) were prepared by emulsion-induced interface anisotropy assembly method, and MPDA NPs modified by human serum albumin (HSA) were used as drug carriers, loaded with alteplase, and constructed HMP@rt- PA nanoparticles, with ROS scavenging ability, can responsively release drugs at the ischemic site.
It is achieved to quickly stabilize drug activity and effectively clear ROS when treating ischemic stroke, improve the microenvironment of the cerebral ischemic site, improve the treatment effect and reduce the risk of toxicity.
Smart Images

Figure CN119015261A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of medical materials, and in particular to the preparation and application of nanoparticle HMP@rt-PA loaded with alteplase for removing active oxygen. Background Art
[0002] Cerebral ischemia, also known as ischemic stroke, is a neurological disease caused by stenosis or blockage of cerebral arteries. Because ischemia can lead to impaired blood supply to the brain, ischemia and hypoxic necrosis of local brain tissue, accumulation of metabolites such as lactic acid, ion imbalance, and inflammatory response, ischemic stroke is a disease with high disability and mortality. Alteplase (rt-PA) is the only drug approved by the U.S. Food and Drug Administration for thrombolytic therapy in the acute phase of ischemic stroke. However, the clinical application of rt-PA is severely limited by its treatment time window. It is generally believed that intravenous thrombolysis with rt-PA within 4.5 hours is the preferred method for treating acute ischemic stroke. Therefore, it is crucial to quickly resolve the symptoms of vascular occlusion during the treatment window and to stabilize the activity of the drug as much as possible.
[0003] In addition, single thrombolytic therapy may cause secondary damage due to failure to block the large amount of reactive oxygen species (ROS) generated by reperfusion, leading to poor prognosis. When reperfusion restores blood flow and oxygen supply to the ischemic brain area, it will also enhance the production of ROS, triggering a series of chain reactions that destroy cell structure in cells, inducing oxidative stress in the body, and further aggravating calcium overload and inflammatory response. Therefore, while relieving the symptoms of cerebral ischemia, the combined use of high-efficiency, low-toxic and safe antioxidants is an effective way to clinically treat ischemic stroke.
[0004] Nanozymes are a type of nanomaterial with unique properties. They have both the unique properties of nanomaterials and catalytic functions, and have broad research prospects in many fields such as chemical engineering, medicine, and agriculture. Among them, in the medical field, they have attracted much attention because of their ability to effectively remove ROS, regulate cell signaling pathways, activate immune responses, and have good biosafety. In addition, nanozymes can also be used as drug delivery platforms to responsively release drugs, which is expected to achieve the effect of improving the microenvironment of the ischemic site and releasing drugs in the early stage. However, at present, there are few studies on nanozymes in the treatment of ischemic stroke. Summary of the invention
[0005] Based on the above, the purpose of this study is to prepare a nanoparticle that can load thrombolytic drugs and remove reactive oxygen species. In addition, according to the characteristics of the carrier, the nanoparticle can effectively remove ROS generated in the brain injury site and after reperfusion, improve the microenvironment of the brain ischemic site, and achieve a combined strategy of drug treatment and improvement of the environment of the injury site.
[0006] The basic scheme provided by the present invention is: mesoporous polydopamine nanoparticles (MPDA NPs) are prepared by an emulsion-induced interfacial anisotropic assembly method, and human serum albumin (HSA)-mesoporous polydopamine nanoparticles (HSA-MPDA) modified with human serum albumin (HSA) are used as drug carriers to load alteplase (rt-PA) drugs to construct human serum albumin-mesoporous polydopamine nanoparticles loaded with alteplase (HMP@rt-PA) for scavenging reactive oxygen species.
[0007] Compared with the existing technology, this study has the following advantages: 1. Use mesoporous polydopamine nanoparticles as drug carriers. Polydopamine (PDA) is a black insoluble biopolymer produced by the self-oxidation of catecholamine neurotransmitters. It has good biocompatibility and is widely used in biomedicine. PDA with abundant reducing groups (such as phenol and catechol) has excellent redox ability and relieves oxidative stress (free radical scavenging) by releasing electrons, which may serve as a potential ROS scavenger. Compared with their non-porous counterparts, MPDANPs can provide high accessibility of active sites and have attracted considerable attention. HSA is an FDA-approved drug. The use of HSA stabilization strategy is beneficial to improve the stability of nanomaterials in solution; 2. By preparing HSA-MPDA with ROS scavenging ability as a carrier of rt-PA, it has pH and ROS responsive properties and can deliver thrombolytic drugs to the ischemic site, achieving a dual strategy of microenvironment improvement and thrombolysis.
[0008] The technical solution adopted by the nanoparticle HMP@rt-PA involved in the present invention is as follows: Step (1) adding HSA solution to MPDA NPs solution and mixing under ultrasonic conditions to form HSA-MPDA solution; Step (2) The HSA-MPDA solution and the rt-PA solution are mixed and centrifuged to obtain HMP@rt-PA.
[0009] Furthermore, the preparation method of HSA-MPDA in step (1) is characterized in that: the preparation method of MPDA NPs comprises the following steps: dissolving dopamine hydrochloride and Pluronic F127 in a mixture of water and ethanol, then adding TMB with stirring, obtaining an emulsion after ultrasonic treatment, dropping an ammonia solution into the emulsion system, centrifuging with water and ethanol after polymerization, heating in a high-pressure reactor at 100°C for 24-36 hours, and collecting by centrifugation to obtain MPDA NPs.
[0010] Furthermore, in step (1), the mass ratio of MPDA NPs to HSA is 1:(1-4), and the mixture is mixed at a temperature of 4-10°C for 2-4h.
[0011] Furthermore, in step (2), the mass ratio of HSA-MPDA to rt-PA is (6-12):1, and the mixture is mixed for 24-36 h. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 Transmission electron microscopy images of MPDA NPs and HMP@rt-PA.
[0013] Figure 2 Particle size diagram of MPDA NPs and HMP@rt-PA measured by dynamic light scattering (DLS).
[0014] Figure 3 Potential diagrams of rt-PA, HAS, MPDA NPs, and HMP@rt-PA measured by dynamic light scattering (DLS).
[0015] Figure 4 The particle size of HMP@rt-PA was measured for seven consecutive days.
[0016] Figure 5 Drug loading and in vitro release of HMP@rt-PA at pH 5.5 and 7.4 and H2O2.
[0017] Figure 6 This is a bar graph of HMP@rt-PA cell viability determined by the CKK8 method.
[0018] Figure 7 This is a curve chart of the change in O2 concentration in H2O2 solutions with different concentrations.
[0019] Figure 8 The in vitro ROS scavenging effects of HSA-MPDA and HMP@rt-PA.
[0020] Fig. 9 The in vitro thrombolytic effect of rt-PA and HMP@rt-PA. DETAILED DESCRIPTION
[0021] The present invention will be further described below through specific implementations, but the specific implementation methods of the present invention are only for explaining the present invention, not for limiting the present invention.
[0022] Example 1 The present embodiment provides a method for preparing rt-PA-loaded nanoparticles HMP@rt-PA: 0.15 g dopamine hydrochloride and 0.10 g Pluronic F127 are dissolved in a mixture of water and ethanol to a volume of 10 mL (1:1), and then 0.20 mL TMB is added with stirring, and ultrasonic dispersion is performed for 2 min to obtain an emulsion, 0.375 mL ammonia solution is dropped into the emulsion system, and after polymerization for 2 h, it is centrifuged 3 to 4 times with water and ethanol, heated in a 100°C high-pressure reactor for 24 h, and centrifuged (12000 rpm, 20 min) to obtain MPDA NPs, MPDA NPs solution (1 mg / mL) is added to HSA solution (1 mg / mL), the mixed solution is cleaned at 4°C with an ultrasonic cleaner for 2 h, HSA-MPDA is collected, 4 mg HSA-MPDA is diluted to 3.5 mL, 0.5 mL of rt-PA solution with a concentration of 1 mg / mL is added, and the mixture is stirred for 24 h, Centrifugation to obtain rt-PA-loaded nanoparticles HMP@rt-PA.
[0023] Comparative Example 1 The present comparative example provides a method for preparing HSA-MPDA nanoparticles without rt-PA loading: 0.15 g dopamine hydrochloride and 0.10 g Pluronic F127 are dissolved in a mixture of water and ethanol with a volume of 10 mL (1:1), and then 0.20 mL TMB is added with stirring, and ultrasonic dispersion is performed for 2 min to obtain an emulsion, 0.375 mL ammonia solution is dropped into the emulsion system, and after polymerization for 2 h, it is centrifuged 3-4 times with water and ethanol, heated in a 100 ° C high-pressure reactor for 24 h, and centrifuged (12000 rpm, 20 min) to obtain MPDA NPs, and the MPDA NPs solution (1 mg / mL) is added to the HSA solution (1 mg / mL), and the mixed solution is cleaned with an ultrasonic cleaner at 4 ° C for 2 h, and HSA-MPDA is collected, that is, nanoparticles HSA-MPDA without rt-PA loading.
[0024] As attached Figure 1 As shown in the figure, TEM characterizes the morphological characteristics of nanoparticles MPDA NPs and HMP@rt-PA. TEM characterizes the morphological characteristics of nanoparticles. It can be seen that MPDA NPs have a clear mesoporous structure. After rt-PA is loaded, the mesoporous structure is no longer clearly visible, indicating the successful loading of rt-PA. HMP@rt-PA presents a more rounded spherical structure, which may be the surface modification of HSA.
[0025] As attached Figure 2As shown in the figure, the particle sizes of MPDA NPs and HMP@rt-PA measured by DLS. The size of MPDA NPs measured by DLS was about 100 nm, and the size of HMP@rt-PA after rt-PA loading and HSA modification was slightly increased to about 119 nm.
[0026] As attached Figure 3 As shown, the potential images of rt-PA, HSA, MPDA NPs and HMP@rt-PA determined by DLS showed that HSA and MPDA NPs were negatively charged, rt-PA was positively charged, and the negative potential of HMP@rt-PA was slightly reduced, indicating the successful loading of rt-PA.
[0027] As attached Figure 4 As shown in the figure, the particle size of HMP@rt-PA was measured for seven consecutive days. The particle size of HMP@rt-PA was measured for seven consecutive days and there was no significant change, indicating that it has good stability.
[0028] As attached Figure 5 As shown in the figure, the drug loading and in vitro release of HMP@rt-PA (under pH 5.5 and 7.4 and H2O2 conditions). rt-PA solutions of different concentrations were prepared, and the rt-PA standard curve was drawn using a high-performance liquid chromatograph (chromatographic column Welch-C18) (left figure). After HMP@rt-PA was destroyed, the rt-PA content was detected and analyzed again. HMP@rt-PA can release rt-PA quickly when destroyed under acidic and H2O2 conditions.
[0029] As attached Figure 6 As shown in the figure, the cell viability of HMP@rt-PA was determined in PC12 and BV2 cells by measuring the effect of different concentrations of HMP@rt-PA on cell viability. The cell viability after treatment with 0-500 μg / mL HMP@rt-PA was above 90%, indicating that HMP@rt-PA has good biosafety.
[0030] As attached Figure 7 As shown in the figure, the results of the H2O2-like enzyme activity analysis of HSA-MPDA and HMP@rt-PA. The H2O2-like enzyme activity of the above two nanoparticles was analyzed by measuring the changes in the dissolved oxygen concentration in the H2O2 solutions of HSA-MPDA and HMP@rt-PA. When HSA-MPDA and HMP@rt-PA were not present, the dissolved oxygen content of the H2O2 solutions of different concentrations remained almost unchanged within 20 min, while after the addition of HSA-MPDA or HMP@rt-PA, the amount of dissolved O2 gradually increased over time. In addition, the higher the H2O2 concentration, the more O2 was produced within 20 min. In H2O2 solutions of different concentrations, the H2O2-like enzyme activity of HMP@rt-PA was always slightly higher than that of HSA-MPDA.
[0031] As attached Figure 8 As shown in the figure, the in vitro ROS scavenging effect of HSA-MPDA and HMP@rt-PA. The neural cell PC12 was selected as a cell model, and H2O2 was used to induce the increase of ROS in PC12 cells. After PC12 cells were co-incubated with HSA-MPDA and HMP@rt-PA for 4 h, the relative fluorescence expression of ROS was observed by flow cytometry and compared with the blank group. The above results show that the nanoparticles have good in vitro ROS scavenging performance.
[0032] As attached Fig. 9 As shown in the figure, the in vitro thrombolytic effects of rt-PA and HMP@rt-PA showed that the blood clots had almost no significant changes after incubation in PBS for 4 h. After treatment with free rt-PA, the blood clots quickly dissolved within 1 h and disappeared completely after 2 h. In the case of only HMP@rt-PA, the blood clots were seen to dissolve after 1 h, and the thrombus dissolution rate reached 80% after 4 h of treatment. In the case of HMP@rt-PA and H2O2, the blood clots were found to be significantly dissolved after 1 h of HMP@rt-PA treatment, and the blood clots were completely dissolved after 4 h, indicating that HMP@rt-PA dissociated in the presence of H2O2, achieving the effective release of rt-PA, thereby achieving the thrombolytic effect.
[0033] The above is only an embodiment of the present invention, but the actual research content is not limited thereto. For those familiar with the field, it is easy to optimize and modify the experiment, so there can be a variety of alternatives or replacements without departing from the scope of the present invention.
Claims
1. A method for preparing nanoparticles HMP@rt-PA loaded with alteplase for scavenging active oxygen, characterized in that; The nanoparticle HMP@rt-PA is mainly composed of human serum albumin-mesoporous polydopamine nanoparticles HSA-MPDA composed of mesoporous polydopamine nanoparticles MPDA NPs and human serum albumin HSA, and the drug alteplase rt-PA is loaded inside the HSA-MPDA to form HMP@rt-PA.
2. The method for preparing HMP@rt-PA according to claim 1, characterized in that: The method comprises the preparation of MPDA NPs, the preparation of HSA-MPDA and the preparation of HMP@rt-PA. The preparation method of HMP@rt-PA comprises the following steps: (1) Add HSA solution to MPDA NPs solution, mix under ultrasonic conditions, and centrifuge to obtain HSA-MPDA; (2) Mix the HSA-MPDA solution and the rt-PA solution and centrifuge to obtain HMP@rt-PA.
3. The method for preparing HMP@rt-PA according to claim 2, characterized in that: The preparation method of MPDA NPs comprises the following steps: (1) Dopamine hydrochloride and Pluronic F127 were dissolved in a mixture of water and ethanol, and then TMB was added with stirring, and an emulsion was obtained after ultrasonic treatment; (2) dropping ammonia solution into the emulsion system, and centrifuging with water and ethanol after polymerization; (3) Heating in a high-pressure reactor for 24-36 h and collecting by centrifugation to obtain MPDA NPs.
4. The preparation method according to claim 2, characterized in that: The mass ratio of MPDA NPs to HSA in step (1) is 1:(1-4).
5. The preparation method according to claim 2, characterized in that: In step (1), the mixing temperature is 4-10°C and the mixing time is 2-4 hours.
6. The preparation method according to claim 2, characterized in that: The mass ratio of HSA-MPDA to rt-PA in step (2) is (6-12):
1.
7. HMP@rt-PA prepared by a preparation method according to any one of claims 2 to 6, which is used in the removal of active oxygen.
Citation Information
Cited By
Preparation method and application of recombinant human serum albumin-arteplase nano-drug
CN120267847A
Preparation method and application of recombinant human serum albumin-alteplase nanomedicine
CN120267847B
